Trapman J - Search Results

1

Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.

Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, van Weerden WM, Jenster G. Marques RB, et al. Among authors: trapman j. Int J Cancer. 2005 Nov 1;117(2):221-9. doi: 10.1002/ijc.21201. Int J Cancer. 2005. PMID: 15900601

2

Evolution of the androgen receptor pathway during progression of prostate cancer.

Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G. Hendriksen PJ, et al. Among authors: trapman j. Cancer Res. 2006 May 15;66(10):5012-20. doi: 10.1158/0008-5472.CAN-05-3082. Cancer Res. 2006. PMID: 16707422 Free article.

3

TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. Hermans KG, et al. Among authors: trapman j. Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871. Cancer Res. 2006. PMID: 17108102

4

Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.

Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Hermans KG, et al. Among authors: trapman j. Cancer Res. 2008 May 1;68(9):3094-8. doi: 10.1158/0008-5472.CAN-08-0198. Cancer Res. 2008. PMID: 18451133

5

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J. Hermans KG, et al. Among authors: trapman j. Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825963

6

Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AJ, van Leenders GJ, de Vos CV, Jenster G, Trapman J. Boormans JL, et al. Among authors: trapman j. Int J Cancer. 2013 Jul 15;133(2):335-45. doi: 10.1002/ijc.28025. Epub 2013 Feb 12. Int J Cancer. 2013. PMID: 23319146

7

The human PC346 xenograft and cell line panel: a model system for prostate cancer progression.

Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma CH, Trapman J, Jenster G. Marques RB, et al. Among authors: trapman j. Eur Urol. 2006 Feb;49(2):245-57. doi: 10.1016/j.eururo.2005.12.035. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16413664 Review.

8

Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.

Hermans KG, van Alewijk DC, Veltman JA, van Weerden W, van Kessel AG, Trapman J. Hermans KG, et al. Among authors: trapman j. Genes Chromosomes Cancer. 2004 Mar;39(3):171-84. doi: 10.1002/gcc.10311. Genes Chromosomes Cancer. 2004. PMID: 14732919

9

Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation.

Verkaik NS, Trapman J, Romijn JC, Van der Kwast TH, Van Steenbrugge GJ. Verkaik NS, et al. Among authors: trapman j. Int J Cancer. 1999 Jan 29;80(3):439-43. doi: 10.1002/(sici)1097-0215(19990129)80:3<439::aid-ijc17>3.0.co;2-v. Int J Cancer. 1999. PMID: 9935187

10

Deletion of chromosomal region 6q14-16 in prostate cancer.

Verhagen PC, Hermans KG, Brok MO, van Weerden WM, Tilanus MG, de Weger RA, Boon TA, Trapman J. Verhagen PC, et al. Among authors: trapman j. Int J Cancer. 2002 Nov 10;102(2):142-7. doi: 10.1002/ijc.10677. Int J Cancer. 2002. PMID: 12385009

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

194 results

Search Page

Filters